title: Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux.
authors.forename: Kit L
authors.initials: KL
authors.lastname: Cheng
authors.forename: Judith
authors.initials: J
authors.lastname: Brody
authors.forename: Craig E
authors.initials: CE
authors.lastname: Warshall
authors.forename: Elaine M
authors.initials: EM
authors.lastname: Sloand
authors.forename: Steven L
authors.initials: SL
authors.lastname: Allen
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D000077425:Fondaparinux; D006457:Hemoglobinuria, Paroxysmal / Q000139:chemically induced* / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000188:drug therapy*; D019338:Polypharmacy; D011134:Polysaccharides / Q000008:administration & dosage*; D012008:Recurrence; D013927:Thrombosis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D011134:Polysaccharides; D000074323:Alemtuzumab; C481642:eculizumab; D000077425:Fondaparinux